| Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... Nature communications 11 (1), 2416, 2020 | 272 | 2020 |
| Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer RR Mishra, N Belder, SA Ansari, M Kayhan, H Bal, U Raza, PG Ersan, ... Clinical Cancer Research 24 (8), 1987-2001, 2018 | 56 | 2018 |
| Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer R Assidicky, UM Tokat, IO Tarman, O Saatci, PG Ersan, U Raza, H Ogul, ... Breast cancer research and treatment 193 (2), 331-348, 2022 | 32 | 2022 |
| TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice M Yildirim, TC Yildirim, N Turay, T Bildik, B Ibibik, I Evcili, PG Ersan, ... Immunology Letters 239, 32-41, 2021 | 27 | 2021 |
| HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin M Biondini, A Kiepas, L El-Houjeiri, MG Annis, BE Hsu, AM Fortier, ... Oncogene 41 (12), 1701-1717, 2022 | 15 | 2022 |
| Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer O Saatci, R Alam, KT Huynh-Dam, A Isik, M Uner, N Belder, PG Ersan, ... Cell Death & Disease 15 (6), 418, 2024 | 9 | 2024 |
| PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview A Adibi, ÜM Tokat, E Özgü, E Aydın, İ Demiray, M Demiray Therapeutic Advances in Medical Oncology 15, 17588359231213841, 2023 | 6 | 2023 |
| Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun 11: 2416 O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... | 5 | 2020 |
| Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020; 11: 2416 O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... | 5 | |
| Exceptional response to MEK inhibition in a patient with RAF1-mutant myxofibrosarcoma: case report and mechanistic overview E Özgü, E Aydin, A Adibi, ÜM Tokat, O Tutar, J Hu, I Demiray, R Kurzrock, ... JCO Precision Oncology 7, e2300299, 2023 | 3 | 2023 |
| Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Nature Communications 14 (1), 6997, 2023 | 3 | 2023 |
| Durable radiologic and molecular complete response following nivolumab in an HNSCC patient with UV signature and HIV A Adibi, ÜM Tokat, E Özgü, N Mamyrov, E Aydın, ŞN Bilgiç, O Tutar, ... Oral Oncology 154, 106859, 2024 | 1 | 2024 |
| Evaluation of the Relationship between Aromatase/Sirtuin1 Interaction and miRNA Expression in Human Neuroblastoma Cells Y Kartal, UM Tokat, P Kelicen-Ugur, S Yılmaz, S Karahan, MT Budak Current molecular pharmacology 16 (6), 609-628, 2023 | 1 | 2023 |
| Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2-Mutant Cholangiocarcinoma E Özgü, ÜM Tokat, A Adibi, ŞN Bilgiç, E Aydın, O Tutar, M Demiray JCO Precision Oncology 9, e2400652, 2025 | | 2025 |
| Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan ÜM Tokat, A Adibi, E Aydın, ŞN Bilgiç, E Özgü, O Tutar, M Demiray Frontiers in Oncology 14, 1484750, 2025 | | 2025 |
| Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and … ÜM Tokat, ŞN Bilgiç, E Aydın, A Adibi, E Özgü, O Tutar, M Demiray Therapeutic Advances in Medical Oncology 16, 17588359241297101, 2024 | | 2024 |
| Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors E Özgü, BG Kaplan, S Sivakumar, ES Sokol, E Aydın, ÜM Tokat, A Adibi, ... BJC reports 2 (1), 77, 2024 | | 2024 |
| Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers ÜM Tokat, A Adibi, E Aydın, E Özgü, ŞN Bilgiç, O Tutar, ... Current Oncology 31 (10), 5838-5849, 2024 | | 2024 |
| Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response W Wofford, J Kim, D Kim, AH Janneh, HG Lee, FC Atilgan, N Oleinik, ... Cell reports 43 (8), 2024 | | 2024 |
| Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib E Aydın, ÜM Tokat, A Adibi, E Özgü, ŞN Bilgiç, M Demiray Frontiers in Oncology 14, 1405170, 2024 | | 2024 |
Ozgur SahinProfessor and Endowed Chair at Medical University of South CarolinaΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα musc.edu